尪痹的中医证型与促炎因子的相关性研究进展

doi:10.3760/cma.j.issn.1007-1245.2022.07.005

国际医药卫生导报 ›› 2022, Vol. 28 ›› Issue (7): 907-911.DOI: 10.3760/cma.j.issn.1007-1245.2022.07.005

尪痹的中医证型与促炎因子的相关性研究进展

张瑀琼¹ 崔宏伟² 于蕾³ 李国华⁴ 吕新亮⁴

¹内蒙古医科大学，呼和浩特　010110； ²内蒙古医科大学附属人民医院内蒙古自治区肿瘤医院科研部，呼和浩特　010020； ³内蒙古自治区中医医院药剂科，呼和浩特　010010； ⁴内蒙古自治区中医医院风湿免疫科，呼和浩特　010010

收稿日期:2022-01-10 出版日期:2022-04-01 发布日期:2022-05-06
通讯作者: 吕新亮，Email：lxl230081@sina.com
基金资助:
内蒙古自治区科技计划项目（CZ000159）

Correlation between traditional Chinese medicine syndromes of Wangbi disease and pro-inflammatory factors

Zhang Yuqiong¹, Cui Hongwei², Yu Lei³, Li Guohua⁴, Lyu Xingliang⁴

¹Inner Mongolia Medical University, Hohhot 010110, China; ²Clinical Medicine Research Center, Affiliated People's Hospital of Inner Mongolia Medical University, Tumor Hospital of Inner Mongolia Autonomous Region, Hohhot 010020, China; ³Department of Pharmacy,Traditional Chinese Medicine Hospital of Inner Mongolia Autonomous Region, Hohhot 010010, China; ⁴Department of Rheumatology and Immunology,Traditional Chinese Medicine Hospital of Inner Mongolia Autonomous Region, Hohhot 010010, China

Received:2022-01-10 Online:2022-04-01 Published:2022-05-06
Contact: Lyu Xinliang, Email: lxl230081@sina.com
Supported by:
Contract Project of Science and Technology Plan in Inner Mongolia Autonomous Region (CZ000159)

摘要/Abstract

摘要： 尪痹最早由现代医家焦树德教授提出，是继“痹症”“历节”“鹤膝风”之后中医界对类风湿关节炎的进一步具体化表达。从最早对本病有记载的《黄帝内经》到现在，历经两千多年后尪痹仍然是医学界公认的难以彻底治愈的疾病之一。各大医家根据自身临床经验对本病的证型不断完善，直到2018年在《类风湿关节炎病证诊疗指南》才有了最为全面的8种证型，其中5种实证分别是寒湿痹阻证、风湿痹阻证、湿热痹阻证、瘀血阻络证、痰瘀痹阻证，3种虚证分别是气阴两虚证、气血两虚证、肝肾不足证。中医从宏观角度在辨证论治原则的指导下收效斐然。西医从微观角度认为本病的发生发展与促炎因子关系密切，其中多种促炎因子的表达随着中医证型的不同有所差异。本文就尫痹发病过程中的中医证型与促炎因子相关性作一综述，探讨中医在治疗尫痹发展中对炎症因子的作用，以期对中医辨证论治和中西医联合用药上有指导作用，进一步提高患者生存质量。

关键词: 尪痹, 类风湿关节炎, 中医证型, 促炎因子, 综述

Abstract:

Wangbi disease was first proposed by the modern physician Professor Jiao Shude. It is a further embodiment of rheumatoid arthritis in the field of traditional Chinese medicine after the "Bizheng", "Lijie", and "Hexifeng". From the earliest record of the disease in the Huang Di Nei Jing to the present, after more than two thousand years, Wangbi disease is still one of the diseases recognized by the medical community that it is difficult to completely cure. Major doctors constantly improve the syndrome types of this disease based on their own clinical experiences. It was not until 2018 that Guidelines for the Diagnosis and Treatment of Rheumatoid Arthritis had the most comprehensive eight types of syndromes. Among them, five kinds of empirical evidences are cold and wet bi syndrome, rheumatism syndrome, hot and humid bi resistance certificate, blood stasis syndrome, and sputum stasis syndrome, and three kinds of deficiency evidences are Qi Yin deficiency certificate, Qi and blood deficiency certificate, and liver and kidney deficiency certificate. From a macro perspective, traditional Chinese medicine has achieved remarkable results under the guidance of the principles of syndrome differentiation and treatment. Western medicine believes that the occurrence and development of this disease are closely related to pro-inflammatory factors from a microscopic view, and the expressions of many pro-inflammatory factors vary in the different types of traditional Chinese medicine syndromes. This article summarizes the relationship between traditional Chinese medicine syndromes and pro-inflammatory factors in the pathogenesis of Wangbi, discusses the role of traditional Chinese medicine in the treatment of Wangbi disease development on inflammatory factors, in order to have a guiding effect on traditional Chinese medicine syndrome differentiation and combined traditional Chinese medicine and western medicine, and further improve the patients' survival quality.

Key words: Wangbi disease, Rheumatoid arthritis, Traditional Chinese medicine syndrome types, Pro-inflammatory factors, Review

张瑀琼, 崔宏伟, 于蕾, 李国华, 吕新亮. 尪痹的中医证型与促炎因子的相关性研究进展[J]. 国际医药卫生导报, 2022, 28(7): 907-911.

Zhang Yuqiong, Cui Hongwei, Yu Lei, Li Guohua, Lyu Xingliang. Correlation between traditional Chinese medicine syndromes of Wangbi disease and pro-inflammatory factors[J]. International Medicine and Health Guidance News, 2022, 28(7): 907-911.

参考文献

[1] 焦树德,王伟钢.尪痹病名及其证治规律的研究[J].浙江中医药大学学报,2009,33(5):681-685.DOI:10.3969/j.issn.1005-5509.2009.05.024.

[2] 中华中医药学会风湿病分会.类风湿关节炎病证结合诊疗指南[J].中医杂志,2018,59(20):1794-1800.DOI:10.13288/j.11-2166/r.2018.20.018.

[3] 焦树德,杜甫云.尪痹的辨证论治[J].中医杂志,1992,33(3):11-13.DOI:10.13288/j.11-2166/r.1992.03.008.

[4] 李满意,刘红艳,陈传榜,等.尪痹的源流及临床意义[J].风湿病与关节炎,2019,8(6):56-60.DOI:10.3969/j.issn.2095- 4174.2019.06.015.

[5] 焦树德.类风湿关节炎从尪痹论治[J].江苏中医药,2008,40(1):5-6.DOI:10.3969/j.issn.1672-397X.2008.01.004.

[6] 李满意,娄玉钤,杨林江.娄多峰教授治疗类风湿关节炎经验总结[J].风湿病与关节炎,2013,2(7):45-50.

[7] 侯雷,马武开.类风湿关节炎中医证候分类临床文献研究[J].中国中西医结合杂志,2014,34(3):279-283.DOI:10.7661/CJIM.2014.03.0279.

[8] 周生花,周计春,刘龙.国医大师周仲瑛教授治疗类风湿关节炎经验[J].中华中医药杂志,2014,29(8):2502-2504.

[9] 吴闵,姚晓玲,王秋燚,等.基于"肾虚邪郁"辨治类风湿关节炎[J].中国中医药信息杂志,2020,27(9):130-132.DOI:10.3969/j.issn.1005-5304.201904223.

[10] 张杰.内湿(痰湿)在类风湿关节炎发病中的意义[J].中国中医药信息杂志,2017,24(12):105-107.DOI:10.3969/j.issn.1005-5304.2017.12.026.

[11] 赵越,晏菁遥,黄闰月,等.近十年治疗类风湿关节炎文献的中医证候分布与遣方用药规律分析[J].中华中医药学刊,2019,37(9):2168-2177.DOI:10.13193/j.issn.1673-7717. 2019.09.029.

[12] 王秀芳,赵衍振,樊冰,等.早期类风湿关节炎患者的临床特点与中医证候分布规律研究[J].风湿病与关节炎,2021,10(8):6-9.DOI:10.3969/j.issn.2095-4174.2021.08.002.

[13] Novikov AA, Aleksandrova EN, Lukina GV. Serum cytokine profile in early and established rheumatoid arthritis[J]. Almanac of Clinical Medicine, 2019, 47(5): 393-399.

[14] 蔡辉,张群燕,郭郡浩,等.类风湿关节炎患者外周血血浆中TNF-α、IL-1β及IL-10的表达及临床意义[J].中华中医药学刊,2017,35(3):519-521.DOI:10.13193/j.issn.1673- 7717. 2017.03.001.

[15] Mateen S, Zafar A, Moin S, et al. Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis[J]. Clin Chim Acta, 2016,455:161-171. DOI: 10.1016/j.cca.2016.02.010.

[16] Kim EY, Moudgil KD. Immunomodulation of autoimmune arthritis by pro-inflammatory cytokines[J]. Cytokine, 2017,98:87-96. DOI: 10.1016/j.cyto.2017.04.012.

[17] 孙凤艳,冯红卫,刘振,等.类风湿性关节炎患者血清细胞因子与病情的相关性研究[J].中外医学研究,2020,18(2):21-23.DOI:10.14033/j.cnki.cfmr.2020.02.009.

[18] Mihara M, Kotoh M, Nishimoto N, et al. Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys[J]. Clin Immunol, 2001,98(3):319-326. DOI: 10.1006/clim.2000.4989.

[19] Hughes-Austin JM, Deane KD, Derber LA, et al. Multiple cytokines and chemokines are associated with rheumatoid arthritis-related autoimmunity in first-degree relatives without rheumatoid arthritis: Studies of the Aetiology of Rheumatoid Arthritis (SERA)[J]. Ann Rheum Dis, 2013,72(6):901-907. DOI: 10.1136/annrheumdis-2012-201505.

[20] 苗正月,蒋金桃,崔国良,等.类风湿关节炎中相关促炎因子和抑炎因子的研究进展[J].医学综述,2021,27(18):3569-3573.DOI:10.3969/j.issn.1006-2084.2021.18.007.

[21] Krishna Priya EK, Srinivas L, Rajesh S, et al. Pro-inflammatory cytokine response pre-dominates immuno-genetic pathway in development of rheumatoid arthritis[J]. Mol Biol Rep, 2020,47(11):8669-8677. DOI: 10.1007/s11033-020-05909-2.

[22] Nakahara H, Song J, Sugimoto M, et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis[J]. Arthritis Rheum, 2003,48(6):1521-1529. DOI: 10.1002/art.11143.

[23] 孟梅,岳正刚,周瑞,等.靶向类风湿关节炎细胞因子与信号通路的治疗药物进展[J].中国药学杂志,2021,56(8):620-625.DOI:10.11669/cpj.2021.08.002.

[24] Kim S, Jeon M, Lee JE, et al. MEK activity controls IL-8 expression in tamoxifen-resistant MCF-7 breast cancer cells[J]. Oncol Rep, 2016,35(4):2398-2404. DOI: 10.3892/or.2016.4557.

[25] Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation[J]. Nat Rev Drug Discov, 2012,11(10):763-776. DOI: 10.1038/nrd3794.

[26] Yuan N, Yu G, Liu D, et al. An emerging role of interleukin-23 in rheumatoid arthritis[J]. Immunopharmacol Immunotoxicol, 2019,41(2):185-191. DOI: 10.1080/08923973.2019.1610429.

[27] 陶娟,汪悦,徐雯,吴斌龙.辨证分型治疗早期类风湿关节炎临床观察[C]//中华中医药学会.中华中医药学会第十六届全国风湿病学术大会论文集,2012:219-221.

[28] 朱海波,何忠斌.类风湿性关节炎中医证型与血清TNF-α、IL-6水平的关系初探[J].中医药导报,2011,17(9):26-27.DOI:10.13862/j.cnki.cn43-1446/r.2011.09.013.

[29] 曹艳红,胡建东.湿热痹阻与寒湿痹阻型类风湿关节炎相关细胞因子客观化研究[J].湖南中医药大学学报,2016,36(10):67-71.

[30] 李明.血清ESR、IL-10和CRP水平与类风湿关节炎患者中医证型的相关性研究[J].实用临床医药杂志,2017,21(24):129-130.

[31] 侯雷,元晓龙,曾苹,等.类风湿关节炎中医证型与IL-17及其相关炎症因子表达的研究[J].中国民族民间医药,2019,28(3):81-86.

[32] 张晓攀,李艳贞,李珊珊,等.类风湿性关节炎治疗药物研究进展[J].药物评价研究,2018,41(10):1906-1910.DOI:10.7501/j.issn.1674-6376.2018.10.031.

尪痹的中医证型与促炎因子的相关性研究进展

Correlation between traditional Chinese medicine syndromes of Wangbi disease and pro-inflammatory factors

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 4

编辑推荐

Metrics

[1]	李诗华, 周慧, 姚俊. miRNA在鼻咽癌中的研究进展[J]. 国际医药卫生导报, 2022, 28(8): 1168-1171.
[2]	周明轩, 李建厂. 藤梨根在恶性肿瘤中的研究进展[J]. 国际医药卫生导报, 2022, 28(8): 1176-1179.
[3]	潘登, 王浩, 吴恒莲, 陈腾云, 邓运明. 基于智能疾病管理系统的类风湿关节炎疾病活动度评估的随机对照研究[J]. 国际医药卫生导报, 2022, 28(7): 937-941.
[4]	代玉, 郭佳, 殷崇望, 毛霞, 刘阳春. 糖尿病患者并发症恐惧评估工具的研究进展[J]. 国际医药卫生导报, 2022, 28(2): 280-283.